Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00346385 · ClinicalTrials.gov registry record · Phase 1
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
A Phase 1 study, sponsored by ImmunoGen.
- Completed
- Registry status
- Phase 1
- Development phase
- 97
- Enrollment target
NCT00346385 is a Phase 1 study that has completed, run by ImmunoGen. The registered enrollment target is 97 participants.
The verdict
NCT00346385, a Phase 1 study, has completed, sponsored by ImmunoGen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 97 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as BB-10901, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of BB-10901 in treating patients with relapsed or refractory solid tumors.
Interventions
- DRUG BB-10901
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2002-03 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00346385
The ClinicalTrials.gov registry entry for NCT00346385 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunoGen, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BB-10901 is the first listed.
NCT00346385 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00346385 about?
NCT00346385 is a clinical study titled "BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors". RATIONALE: Monoclonal antibodies, such as BB-10901, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and ...
What is the current status of trial NCT00346385?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2002-03. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00346385?
The interventions under investigation include: BB-10901 (DRUG).
Who is sponsoring clinical trial NCT00346385?
This trial is sponsored by ImmunoGen, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.